26218-75-7

Usage

Chemical Properties

White to off-white solid

InChI:InChI=1/C7H6BrNO2/c1-11-7(10)5-3-2-4-6(8)9-5/h2-4H,1H3

Upstream product

• 186581-53-3 diazomethane 
• 21190-87-4 6-bromo-pyridine-2-carboxylic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 34160-40-2 6-bromo-2-pyridinecarbaldehyde 
• 626-05-1 2,6-Dibromopyridine 

Downstream Products

• 33674-96-3 2-bromo-6-(hydroxymethyl)pyridine 
• 476472-00-1 1-(6-bromo-pyridin-2-yl)-2-quinolin-4-yl-ethanone 
• 25194-52-9 6-bromo-pyridine-2-carboxylic acid amide 
• 888969-42-4 6-[2-(3,4,5-trimethoxy-phenylamino)-pyrrolo[2,3-d]pyrimidin-7-yl]-pyridine-2-carboxylic acid methyl ester 
• 908288-81-3 C₃₀H₃₄N₂O₃ 
• 1162648-96-5 C₁₃H₁₀ClNO₂ 
• 923928-18-1 6-(4-Trifluoromethoxy-phenyl)-pyridine-2-carboxylic acid methyl ester 
• 206127-25-5 6-phenylpyridine-2-carboxylic acid methyl ester 
• 203573-76-6 2,2'-dipyridyl-6-carboximidic acid methyl ester 
• 1210419-37-6 methyl 6-(2-fluoro-5-formylphenyl)picolinate 
• 1261944-97-1 C₁₂H₇Cl₂NO₂ 
• 1333376-38-7 C₂₀H₁₆Cl₂N₂O 
• 1333376-35-4 C₁₃H₉Cl₂NO₂ 
• 98436-83-0 methyl 6-cyanopicolinate 

Relevant academic research and scientific papers

A Family of Highly Emissive Lanthanide Complexes Constructed with 6-(Diphenylphosphoryl)picolinate

We report a novel family of lanthanide complexes Ln(DPPOP)3 (Ln = Pr, Nd, Sm, Eu, Tb, Dy, Er, and Yb) employing anionic tridentate (O∧N∧O) ligand 6-(diphenylphosphoryl)picolinate (DPPOP). Crystal structures of the complexes reveal that each lanthanide ion is nine-coordinated by three tridentate ligands. In the crystals, 1D channels are found, which can absorb and eliminate water reversibly. DPPOP possesses high triplet energy and can sensitize a series of lanthanide ions. An energy transfer mechanism is proposed through the higher excited states of the lanthanide ions. In the solid state, remarkably high quantum yields in the visible range are obtained: 81percent for Eu(III), 97percent for Tb(III), 13percent for Dy(III), and 4percent for Sm(III) complex.

Bis(pyrazolato) Bridged Diiron Complexes: Ferromagnetic Coupling in a Mixed-Valent HS-FeII/LS-FeIII Dinuclear Complex

Using a new bis(tridentate) compartmental pyrazolate-centered ligand HL, the bis(pyrazolato)-bridged diiron complex [L2FeII2][OTf]2 (1) and its singly oxidized mixed-valent congener [L2FeIIFeIII][OTf]3 (2) have been synthesized and structurally characterized. While 1 features two HS-FeII ions coordinated to two cis-axial pyridine moieties in a highly distorted octahedral environment, the metal ions in 2 are coordinated by the ligand strand in a trans-axial configuration. Very different Fe–N bond lengths and distinctly different coordination polyhedra are associated with pronounced valence localization in the case of 2. The electronic structures and magnetic properties of 1 and 2 have been further investigated by M?ssbauer spectroscopy and variable temperature magnetic susceptibility measurements. In the case of 1, weak antiferromagnetic coupling is observed between the two HS-FeII ions (J = –0.6 cm–1), while the HS-FeII and LS-FeIII ions in 2 are ferromagnetically coupled (J = +5.2 cm–1) to give an ST = 5/2 ground state with significant zero-field splitting (DFe(II) = 2.3 cm–1). The findings are rationalized with the help of DFT computations.

Apoptosis signal regulating kinase inhibitor and application thereof

The invention discloses an apoptosis signal regulating kinase inhibitor and an application thereof. The apoptosis signal regulating kinase inhibitor is a compound represented by general formula I, anda tautomer or a pharmaceutically acceptable salt thereo

ASK1 ISOINDOLIN-1-ONE INHIBITORS AND METHODS OF USE THEREOF

Isoindolin-1-one compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoindolin-1-one compound or analogs thereof, in the treatment of disorders characterized by the activ

FUSED BICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE

Fused bicyclic compounds and uses thereof in medicine. In particular, provided are fused bicyclic compounds used as ASK1 active regulator and and use of the compounds in the manufacture of a drug for treating a disease regulated by ASK1. Further provided are a pharmaceutical composition and a method of treating a disease regulated by ASK1 comprising administering the compounds or pharmaceutical composition thereof.

Quantum Yields over 80% Achieved in Luminescent Europium Complexes by Employing Diphenylphosphoryl Tridentate Ligands

Four tridentate europium(III) complexes containing a diphenylphosphoryl group are prepared with strong bonding between the ligands and centered ion, convinced by crystal structures. Compared to their parent bidentate complexes, the tridentate complexes di

Small Molecule Analogs of the Nemo Binding Peptide

The invention is directed to a method of inhibiting, within a living cell, the interaction between NF-κB essential modulator (“NEMO”) with IκB kinase-β (IKK-β) at the NEMO binding domain (NBD), comprising exposing the cell to an effective amount or concentration of a compound of the invention, a NEMO-binding domain analog (NBDA). The invention is further directed to a method of treating a condition in a patient, wherein inhibiting the interaction between NF-κB essential modulator (“NEMO”) with IκB kinase-β (IKK-β) at the NEMO binding domain (NBD) is medically indicated, comprising administering to the patient an effective dose of a compound of the invention. Conditions that can be treated by a method of the invention includes muscular dystrophy, asthma, inflammatory bowel disease, multiple sclerosis, Parkinson's Disease, arthritis, diabetes, graft versus host disease, accelerated aging, heart ischemia, cancer, UV-induced skin damage, or an age-related pathology.

INDAZOLE AND AZAINDAZOLE COMPOUNDS AS IRAK-4 INHIBITORS

The present invention provides indazole and aza indazole compounds of formula (I) or (II) and pharmaceutically acceptable salts thereof, and their use to inhibit IRAK-4 and/or for the treatment of diseases or disorders induced by IRAK-4.

Structure-activity relationships of small molecule autotaxin inhibitors with a discrete binding mode

Autotaxin (ATX) is a secreted enzyme responsible for the hydrolysis of lysophosphatidylcholine (LPC) to the bioactive lysophosphatidic acid (LPA) and choline. The ATX-LPA signaling pathway is implicated in cell survival, migration, and proliferation; thus, the inhibition of ATX is a recognized therapeutic target for a number of diseases including fibrotic diseases, cancer, and inflammation, among others. Many of the developed synthetic inhibitors for ATX have resembled the lipid chemotype of the native ligand; however, a small number of inhibitors have been described that deviate from this common scaffold. Herein, we report the structure-activity relationships (SAR) of a previously reported small molecule ATX inhibitor. We show through enzyme kinetics studies that analogues of this chemotype are noncompetitive inhibitors, and by using a crystal structure with ATX we confirm the discrete binding mode.

Design, Synthesis, and Evaluation of Novel Auxin Mimic Herbicides

Due to the key roles of auxins as master regulators of plant growth, there is considerable interest in the development of compounds with auxin-like properties for growth management and weed control applications. Herein, we describe the design and multiste